Dermira to Present at 17th Annual Needham Healthcare Conference
20 mars 2018 08h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 mars 2018 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Cowen & Company 38th Annual Healthcare Conference
08 mars 2018 08h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
05 mars 2018 07h59 HE
|
Dermira, Inc.
Company expects to discontinue the programConference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT MENLO PARK, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM),...
Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
22 févr. 2018 16h01 HE
|
Dermira, Inc.
Olumacostat glasaretil topline Phase 3 data expected Q1 2018FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018Lebrikizumab Phase 2b study enrolling patients and...
New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology
17 févr. 2018 18h30 HE
|
Dermira, Inc.
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new...
Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference
12 févr. 2018 08h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference
09 févr. 2018 08h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 févr. 2018 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
31 janv. 2018 08h30 HE
|
Dermira, Inc.
Study expected to enroll approximately 275 patientsTopline results expected in the first half of 2019TREBLE Phase 2 proof-of-concept results published in the Journal of the American Academy of...